Clopidogrel Resistance Rates in Patients Undergoing Transcarotid Artery Revascularization in a Community Center
Muhammad Owais Abdul Ghani1, Cameron D Moore1, Alex Schneller1, John Newn1, Katelin Maggard1, Shane O’Keeffe2, Magendran Danapal1
1University of Kentucky Bowling Green Campus, Bowling Green, KY;2University of Kentucky, Bowling Green, KY
INTRODUCTION: Clopidogrel is administered perioperatively to prevent thrombosis in patients undergoing Transcarotid artery revascularization (TCAR), however data on resistance rates is not robust. This study aims at quantifying Clopidogrel resistance and comparing demographics and complications versus Clopidogrel Responders.METHODS: We retrospectively identified and divided patients into 2 groups based on preoperative P2Y12 level as Clopidogrel responders and Clopidogrel non-responders and performed univariate analysis on demographics and 30-day complication rates between these groups. Clopidogrel Non-Responders were given ticagrelor instead. Continuous data was analyzed using parametric tests after determining normality using the Kolmogorov-Smirnov test. Categorical variables were analyzed using Chi-square test Fisher's exact tests where applicable. RESULTS: In our cohort of 76 patients, the Plavix resistance rate was 20%. There were no significant differences in demographics between responders and non-responders however the latter had a higher complication rate (37.5% vs 8.3%; p=0.01) attributed mostly to a higher rate of dysrhythmias. There were no statistically significant differences in stroke, access site complications, cranial nerve injury, and hyperperfusion syndrome (Table 1) . CONCLUSIONS:The observed Clopidogrel resistance rate of 20% aligns with rates reported in previous studies on carotid artery interventions. Importantly, our study revealed a significant association between Clopidogrel resistance and postoperative complications. This underscores the clinical significance of identifying Clopidogrel non-responders before TCAR procedures. These patients may require closer monitoring and alternative antiplatelet therapy selection, other than ticagrelor. Further investigation with larger and more diverse patient cohorts is needed. Ultimately, personalized medicine based on Clopidogrel responsiveness may play a crucial role in improving the outcomes of TCAR procedures and reducing postoperative complications.
| Clopidogrel Responders (n=60) | Clopidogrel Non-Responders (n=16) | P-value | |
| Overall Complications | 5 (8.3) | 6 (37.5) | 0.01 |
| Dysrhythmia | 1 (1.7) | 4 (25) | 0.01 |
| TIA/Stroke | 1 (1.7) | 0 | 1.00 |
| Reperfusion Syndrome | 0 | 1 (6.3) | 0.21 |
| Access site | 5 (8.3) | 3 (18.8) | 0.35 |
| Cranial Nerve Injury | 1 (1.7) | 0 | 1.00 |
| Reperfusion Syndrome | 0 | 1 (6.3) | 0.21 |
Back to 2024 Abstracts